HomeComparePFLT vs SYK

PFLT vs SYK: Dividend Comparison 2026

PFLT yields 15.85% · SYK yields 1.04%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFLT wins by $35.1K in total portfolio value
10 years
PFLT
PFLT
● Live price
15.85%
Share price
$7.76
Annual div
$1.23
5Y div CAGR
5.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$78.4K
Annual income
$9,644.04
Full PFLT calculator →
SYK
SYK
● Live price
1.04%
Share price
$326.10
Annual div
$3.40
5Y div CAGR
46.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$43.3K
Annual income
$8,282.98
Full SYK calculator →

Portfolio growth — PFLT vs SYK

📍 PFLT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPFLTSYK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PFLT + SYK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PFLT pays
SYK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PFLT
Annual income on $10K today (after 15% tax)
$1,347.29/yr
After 10yr DRIP, annual income (after tax)
$8,197.43/yr
SYK
Annual income on $10K today (after 15% tax)
$88.62/yr
After 10yr DRIP, annual income (after tax)
$7,040.53/yr
At 15% tax rate, PFLT beats the other by $1,156.90/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PFLT + SYK for your $10,000?

PFLT: 50%SYK: 50%
100% SYK50/50100% PFLT
Portfolio after 10yr
$60.9K
Annual income
$8,963.51/yr
Blended yield
14.73%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SYK right now

PFLT
Analyst Ratings
5
Buy
5
Hold
Consensus: Buy
Price Target
$10.00
+28.9% upside vs current
Range: $9.50 — $10.50
Altman Z
0.3
Piotroski
4/9
SYK
Analyst Ratings
1
Strong
35
Buy
14
Hold
Consensus: Buy
Price Target
$428.67
+31.5% upside vs current
Range: $390.00 — $469.00
Altman Z
4.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PFLT buys
0
SYK buys
0
No recent congressional trades found for PFLT or SYK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPFLTSYK
Forward yield15.85%1.04%
Annual dividend / share$1.23$3.40
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR5.7%46.2%
Portfolio after 10y$78.4K$43.3K
Annual income after 10y$9,644.04$8,282.98
Total dividends collected$47.2K$21.0K
Payment frequencyquarterlyquarterly
SectorBDCHealthcare
Analyst consensusBuyBuy
Analyst price target$10.00$428.67

Year-by-year: PFLT vs SYK ($10,000, DRIP)

YearPFLT PortfolioPFLT Income/yrSYK PortfolioSYK Income/yrGap
1← crossover$12,375$1,675.40$10,852$152.43+$1.5KPFLT
2$15,290$2,048.18$11,838$226.03+$3.5KPFLT
3$18,860$2,499.79$13,004$336.89+$5.9KPFLT
4$23,226$3,046.02$14,420$505.63+$8.8KPFLT
5$28,558$3,705.62$16,195$766.09+$12.4KPFLT
6$35,058$4,500.87$18,504$1,175.64+$16.6KPFLT
7$42,970$5,458.17$21,635$1,835.40+$21.3KPFLT
8$52,586$6,608.75$26,082$2,932.10+$26.5KPFLT
9$64,257$7,989.52$32,737$4,829.68+$31.5KPFLT
10$78,399$9,644.04$43,312$8,282.98+$35.1KPFLT

PFLT vs SYK: Complete Analysis 2026

PFLTBDC

PennantPark Floating Rate Capital Ltd. is a business development company. It seeks to make secondary direct, debt, equity, and loan investments. The fund seeks to invest through floating rate loans in private or thinly traded or small market-cap, public middle market companies. It primarily invests in the United States and to a limited extent non-U.S. companies. The fund typically invests between $2 million and $20 million. The fund also invests in equity securities, such as preferred stock, common stock, warrants or options received in connection with debt investments or through direct investments. It primarily invests between $10 million and $50 million in investments in senior secured loans and mezzanine debt. It seeks to invest in companies not rated by national rating agencies. The companies if rated would be between BB and CCC under the Standard & Poor's system. The fund invests 30% is invested in non-qualifying assets like investments in public companies whose securities are not thinly traded or do not have a market capitalization of less than $250 million, securities of middle-market companies located outside of the United States, high-yield bonds, distressed debt, private equity, securities of public companies that are not thinly traded, and investment companies as defined in the 1940 Act. Under normal conditions, the fund expects atleast 80 percent of its net assets plus any borrowings for investment purposes to be invested in Floating Rate Loans and investments with similar economic characteristics, including cash equivalents invested in money market funds. It expects to represent 65 percent of its portfolio through senior secured loans. In case of floating rate loans, it holds investments for a period of three to ten years.

Full PFLT Calculator →

SYKHealthcare

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.

Full SYK Calculator →
📬

Get this PFLT vs SYK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PFLT vs SCHDPFLT vs JEPIPFLT vs OPFLT vs KOPFLT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.